In vivo antiplasmodial potential of aqueous seed extract of Ricinus communis

Peace ME. Ubulom1*, Ette O Ettebong2, Edidiong J. Udofa3, Rachel S Inyang Etuk3

1Department of Animal and Environmental Biology, Faculty of Science, University of Uyo, Uyo, Nigeria
2Department of Clinical Pharmacology and Therapeutics, Faculty of Clinical Sciences, University of Uyo, Uyo, Nigeria
3Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Uyo, Uyo, Nigeria

*Corresponding author: Peace ME. Ubulom, Email: upema84@yahoo.com

Abstract

Introduction: Ricinus communis is used by the people of Niger-Delta region of Nigeria, for the treatment of various ailments, especially malaria. This study evaluated the antiplasmodial potentials of the aqueous seed extract of R. communis, using Plasmodium berghei berghei.

Methods: Acute toxicity study was carried out to determine the median lethal dose (LD50) of the extract. Antiplasmodial effect of the extract was assessed in suppressive, repository/prophylactic and curative models, using Swiss albino mice (15-29 g). Mice were infected intraperitoneally with 0.2 mL of parasitized blood. Extract doses administered were 54.77, 109.54 and 164.32 mg/kg/d of the seed extract and each dose had 6 replicates. Artesunate (5 mg/kg/d) and pyrimethamine (1.2 mg/kg/d) were used as standard drugs, while distilled water (10 mL/kg/d) served as control.

Results: Acute toxicity study produced LD50 of 547.72 mg/kg. The extract demonstrated a dose-dependent reduction in parasitaemia in all tests. At the end of 4-day test, suppressive effect of 20.80, 49.00, 75.00 and 88.40% were obtained for doses 54.77, 109.54 and 164.32 mg/kg/d of the seed extract and artesunate, respectively. In the repository test pyrimethamine was more potent (72.26%) than the seed extract (9.47%–51.42%). The extract also exhibited appreciable curative effect. The activity of the seed extract was significant when compared with the control (P<0.05). Mice treated with the seed extract and drugs survived for longer duration than the control group.

Conclusion: The aqueous seed extract of R. communis has antiplasmodial potential and its active principle should be elucidated and further investigated to help in the ongoing fight against malaria.

Implication for health policy/practice/research/medical education:

The aqueous seed extract of Ricinus communis has antiplasmodial potential which may be useful in the ongoing fight against malaria.

Please cite this paper as: Ubulom PM, Ettebong EO, Udofa EJ, Inyang Etuk RS. In vivo antiplasmodial potential of aqueous seed extract of Ricinus communis. J Herbmed Pharmacol. 2019;8(2):x-x. doi: 10.15171/jhp.2019.xx.

Introduction

Malaria is a public health challenge with several people at risk of infection. The populations at risk reside mainly in tropical and sub-tropical regions of the world with African countries accounting for the largest burden of the disease (1). The vast majority of cases occur in children under the age of five years and pregnant women. The disease is caused by Plasmodium parasites, transmitted through the bite of infected female Anopheles mosquitoes. Different species of Plasmodium affect humans. Of these, Plasmodium falciparum is the most deadly, leading to many fatal complications (2,3). Tremendous gains have been made in the fight against malaria, as attributed to the adoption of artemisinin-based combination therapy (ACT) and the scale up intervention efforts such as the use of long-lasting insecticide-treated net (LLIN), intermittent preventive therapy (IPT) for pregnant women, vector control measures and increased funding (4). However, owing to the development of resistance by malaria parasites to currently available drugs current tools and treatments are insufficient to achieve elimination in many countries (5). Besides, there is no commercially available malaria vaccine despite intense research and development effort (6). The aforementioned reasons
make the development of novel antimalarial agents urgent. There have been many validations of traditional remedies through scientific research (7-11). Ricinus communis Linn., also known as castor oil plant is a species of flowering plant, in the family Euphorbiaceae. Although indigenous to Eastern Africa and the Mediterranean basin is distributed widely across the world and widespread in tropical regions, tropical Africa inclusive (12). It is commonly called Ogiri-Okepei and Eto adan-ukebe (the plant of enema) in the Igbo and Ibibio speaking parts of Nigeria, respectively. Its pharmaceutical and industrial uses have been reported and these are attributed to its rich phytochemical components (13).

This study was carried out to explore the in vivo antiplasmodial efficacy of crude aqueous seed extract of R. communis in P. berghei infected albino mice.

Materials and Methods
Plant preparation
The plant R. communis was obtained from a local farm in Itak Ikot Akap Village, Ikono Local Government Area, Akwa Ibom State, Nigeria, in November, 2016. Taxonomic keys for the identification of this plant were obtained from the Department of Pharmacognosy and Natural Medicine, Faculty of Pharmacy, University of Uyo, Nigeria. Herbarium specimen with voucher number UUPH31P was prepared and deposited in the herbarium of the same department, for future referencing. The seeds of R. communis were thoroughly washed and air–dried for 21 days. This was followed by pulverization and cold extraction, for 48 hours (with periodic stirring), using distilled water, as the extraction solvent. The crude liquid extract was obtained by filtration thrice using a sterile muslin cloth and twice using Whatman No. 1. filter paper and non-absorbent cotton wool in a filter funnel. The liquid extract was subsequently concentrated to dryness, in vacuo, at a temperature of 40°C, using a rotary evaporation. The concentrated extract obtained was stored in a refrigerator prior to use.

Experimental animals
Swiss albino mice of both sexes weighing 15–29 g were obtained from the Animal House of the Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Uyo. They were maintained according to standard guidelines and fed with animal feed pellets and water ad libitum.

Acute toxicity study
This was carried out to determine the safety profile of the seed extract. Doses of the aqueous seed extract of R. communis ranging from 50-5000 mg/kg were administered through the oral route to Swiss albino mice. Mice were first of all divided into 7 groups of 3 mice each. The animals were observed for visible signs of toxicity and death. The median lethal dose (LD₅₀) was determined using the method of Lorke (14) as:

\[ LD_{50} = \sqrt{AB} \]

Where A = Maximum dose producing 0% mortality
B = Minimum dose producing 100% mortality

Parasite species used for the study and preparation of inoculum
Parasites used for the experiments reported in this study were Plasmodium berghei berghei (Strain no. NK 65 merozoites). They were obtained from Nigeria Institute for Medical Research (NIMR), Lagos. These parasites were maintained by sub passage in mice.

Blood samples were obtained from the parasitized donor mouse via cardiac puncture. This was stored in sterile heparinized bottle. The inoculum was prepared by diluting 2 mL of the parasitized blood with 10 mL of sterile normal saline, to obtain the final inoculum of 0.2 mL (1.0 × 10⁷), which is the standard inoculum for the infection of a single mouse (15, 16).

Preparation of drugs and stock solution of the seed extract
The purity of the standard drugs (artesunate and pyrimethamine) were ascertained by identification test and melting point determination described by WHO in the International Pharmacopoeia (17).

Artesunate (50 mg) was dissolved in 100 mL distilled water while pyrimethamine (25 mg) was dissolved in 10mL distilled water to obtain the stock solutions, from which doses of 5 mg/kg/d and 1.2 mg/kg/d of artesunate and pyrimethamine respectively, were prepared for subsequent administration. Values for 10%, 20% and 30% of the median lethal dose (LD₅₀) were determined and used as the doses for the study.

Determination of antiplasmodial activity
Suppressive test
The suppressive activities of the seed extract and the standard drug, artesunate were evaluated using the method of Okokon and Nwafor (18). Thirty albino mice were used for the study and were randomly divided into five groups of 6 mice each. On the first day (D₁) each mouse received (intraperitoneally) 0.2 mL of infected blood containing P. berghei. Thereafter, mice in groups 1, 2 and 3 received 54.77, 109.54 and 164.32 mg/kg/d of the seed extract respectively, via the oral route. Mice in group 4 received 5 mg/kg/d of artesunate while group 5 mice received 10 mL/kg/d of distilled water (control). All administrations (extract, drug and distilled water) were done daily for 4 days. On the fifth day (D₅), thin blood smears were made on microscope slides, using blood obtained from the tip of the tail of each mouse. The smears were stained with Giemsa stain and examined under the oil immersion objective of a microscope to determine the extent of
parasite clearance. This was done by counting the number of parasitized erythrocytes out of 200 erythrocytes in random fields of the microscope. Formulae used were:

\[
\% \text{parasitaemia} = \left( \frac{\text{No. of parasitized erythrocytes}}{\text{Total No. of erythrocytes counted}} \right) \times 100 \quad (1)
\]

Average percentage chemosuppression \[
= \frac{A - B}{A} \times 100 \quad (2)
\]

Where \( A \) is the average percentage parasitaemia in the control group and \( B \) is the average percentage parasitaemia in the test group.

**Prophylactic test**

Mice were treated before being infected with the parasite *P. berghei berghei*. Thirty mice were also used for this test and they were divided into 5 groups of 6 mice per group. Albino mice in groups 1, 2 and 3 received the same treatment as in the suppressive model except that mice in group 4 each received 1.2 mg/kg/d of pyrimethamine as the standard drug. They received treatment for 3 days. On the fourth day (D4), each mouse was infected intraperitoneally with 0.2 mL of blood containing 1.0 × 10⁷ *P. berghei berghei* parasitized erythrocytes. After 72 hours of parasite inoculation, blood samples were obtained from the tip of the tail of each mouse on alternate days within the treatment period (i.e., D2, D4, D6). Blood samples collected were used to prepare thin films and observed for schizonticidal efficacy of the extract and drug, as described for the suppressive test.

The mean survival time (MST) was determined for each group, over a period of 30 days, using the formula:

\[
\text{MST} = \left( \frac{\text{Number of days survived}}{\text{Total number of days (30)}} \right) \times 100 \quad (3)
\]

**Data analysis**

Results were expressed as multiple comparisons of mean ± standard error of the mean (SEM). Significance was determined using one-way analysis of variance (ANOVA). A probability level of 5% or less was taken as significant.

**Results**

**LD₅₀ value of the seed extract of Ricinus communis**

The medium lethal dose (LD₅₀) of the aqueous seed extract of *R. communis* was 547.72 mg/kg.

**Antiplasmodial activity**

After oral treatment with the various doses of the seed extract of *R. communis*, there was significant decrease in parasitaemia in all models. This decrease was observed to be dose-dependent (Tables 1, 2 and 3).

In the suppressive test, the doses of the aqueous extract of *R. communis* used in this test which were 54.77, 109.54 and 164.32 mg/kg resulted in suppressive effect of 20.80, 49.00 and 75.00%, respectively (Table 1). This decrease in parasitaemia was significant when compared with the control (P<0.05). Artesunate produced the highest chemosuppressive effect of 88.40%.

In the prophylactic test, average percentage chemosuppression of 9.47, 21.58 and 51.42% was obtained and the doses used were 54.77, 109.54 and 164.32 mg/kg of the extract, respectively. The decrease in parasitaemia observed was also significant when compared with the control group (P<0.05). The use of the standard drug (pyrimethamine) resulted in a decrease in parasitaemia (72.26%) and this decrease was also significant (P<0.05), when compared with the results obtained in the control group (Table 2).

In the curative test, there was a progressive dose- and time-dependent reduction in parasitaemia on

| Table 1. Suppressive effect of the aqueous seed extract of Ricinus communis on Plasmodium berghei in infected mice |
|---------------------------------------------------------------|
| **Treatment** | **Dosage (mg/kg)** | **Mean parasite density x 10⁷** | **Mean % chemosuppression** |
| Distilled water (control) | 10 | 149.0 ± 0.28 | - |
| Artesunate | 5 | 17.30 ± 0.92* | 84.40 |
| *R. communis* | 54.77 | 118.00 ± 0.35* | 20.80 |
| *R. communis* | 109.54 | 76.00 ± 0.59* | 49.00 |
| *R. communis* | 164.32 | 37.30 ± 0.73* | 75.00 |

Values are expressed as mean ± SEM, n=6.

*Significant (P < 0.001) compared with control.
Table 2. Prophylactic effect of the aqueous seed extract of *Ricinus communis* on *Plasmodium berghei* in infected mice

| Treatment          | Dosage (mg/kg) | Mean parasite density x 10^7 | Mean % chemosuppression |
|--------------------|----------------|-----------------------------|-------------------------|
| Distilled water    | 10             | 190.0 ± 0.12                | -                       |
| Pyrimethamine      | 1.2            | 52.7 ± 0.74*                | 72.26                   |
| *R. communis*      | 54.77          | 172.0 ± 1.32*               | 9.47                    |
| *R. communis*      | 109.54         | 149.0 ± 0.19*               | 21.58                   |
| *R. communis*      | 164.32         | 92.3 ± 1.37*                | 51.42                   |

Values are expressed as mean ± SEM, n=6.
*Significant (P < 0.001) compared with control.

Table 3. Antiplasmodial effect of the aqueous seed extract of *Ricinus communis* during established infection (curative effect)

| Treatment          | Dosage (mg/kg) | % Reduction in parasitaemia/day
|--------------------|----------------|--------------------------------|
|                    |                | Day 2                           |
| Distilled water    | 10             | 135.0 ± 1.17                    |
| Artesunate         | 5              | 102.0 ± 0.76*                   |
| *R. communis*      | 54.77          | 119.0 ± 0.57*                   |
| *R. communis*      | 109.54         | 82.7 ± 0.92*                    |
| *R. communis*      | 164.32         | 74.7 ± 0.56*                    |

| Treatment          | Dosage (mg/kg) | % Reduction in parasitaemia/day
|--------------------|----------------|--------------------------------|
|                    |                | Day 4                           |
| Distilled water    | 10             | 147.0 ± 0.56                    |
| Artesunate         | 5              | 83.3 ± 1.52*                    |
| *R. communis*      | 54.77          | 70.7 ± 0.76*                    |
| *R. communis*      | 109.54         | 63.3 ± 1.38*                    |
| *R. communis*      | 164.32         | 60.43 ± 0.43*                   |

| Treatment          | Dosage (mg/kg) | % Reduction in parasitaemia/day
|--------------------|----------------|--------------------------------|
|                    |                | Day 6                           |
| Distilled water    | 10             | 158.0 ± 1.12                    |
| Artesunate         | 5              | 16.7 ± 0.56*                    |
| *R. communis*      | 54.77          | 32.7 ± 0.74*                    |
| *R. communis*      | 109.54         | 21.0 ± 0.53*                    |
| *R. communis*      | 164.32         | 16.0 ± 0.36*                    |

Values are expressed as mean ± SEM, n=6.
*Significant (P < 0.001) compared with control.

administration of the extract as revealed by the results of the curative test (Table 3) compared to control group. No curative effect was observed in the control, rather an increase in parasitaemia was observed.

Mice in extract treated groups survived longer (11.4 ± 0.21 and 14.3 ± 0.92 days) than mice in the control group (10.3 ± 0.21 days). Mice treated with artesunate survived longest for 20.7 ± 0.47 days (Table 4).

Discussion

*Plasmodium berghei berghei* is used in predicting treatment outcomes of any suspected antimalarial plant, due to its high sensitivity, making it the appropriate parasite for antiplasmodial study (20). The median lethal dose (LD₅₀) of the aqueous seed extract of *R. communis* which was established at 547.72 mg/kg indicates that the extract is only slightly toxic, according to Loomis and Hayes (21). Thus, it is relatively safe. Ezenobi et al (13) in their research on the phytochemical composition of *R. communis* seeds reported that phytochemicals in the seeds included alkaloids, saponins, flavonoids, tannins, phenols and steroids. The pharmacological activity of the seeds of this plant has been attributed to the presence of these phytochemicals. For instance, it is reported that the seeds of *R. communis* possess antimicrobial activity against important pathogenic organisms (22).

The antimalarial properties of a large number of medicinal plants have been attributed to the presence of alkaloids (23,24). Saponins are known to inhibit the growth of *P. falciparum* (25) and to elicit antimalarial efficacy (26). Saponins have also been found to be detrimental to many infections protozoans (27). The antimalarial potential of plant products containing flavonoids had earlier been reported. It has also been reported that flavonoids exhibited significant antiplasmodial activity against different strains of malaria parasite. Although the mechanism of action of the seed extract of *R. communis* has not yet been elucidated, the secondary metabolites present in the extract may have elicited the observed antiplasmodial activity either singly or in synergy (28,29).

The decrease in parasitaemia observed in all models in this study is an indication that the seeds of *R. communis* have antiplasmodial potentials. A compound is considered active when percentage suppression in parasitaemia is 30% or more (30). Thus, the 49 and 75% chemosuppression obtained when extract doses 109.54 and 164.32 mg/kg respectively, were used in the 4-day test, for instance is appreciable. That the various doses of the seed extract could not produce suppression comparable to that of the standard drugs (artesunate and pyrimethamine), could be
attributed to the fact that the extract is in its crude form. It is hoped that purified fractions and subsequent elucidation of the active principle(s) in the seed of *R. communis* would give better results (improved performance).

The observed mean survival time (MST) of mice treated with various doses of the extract which was longer when compared with the control group, treated with distilled water is attributed to the antiplasmodial efficacy of the extract. However, the group treated with the standard drug (artesunate) survived for longer duration than the extract treated groups.

**Conclusion**

The aqueous seed extract of *R. communis* demonstrated appreciable suppressive, prophylactic and curative antimalarial activities in vivo and these effects were dose-dependent and significant when compared to the control group. The extract-treated groups survived longer than those of negative control group. These depict the antimalarial effectiveness of the extract. The plant is relatively safe and may be exploited in the ongoing fight against malaria.

**Acknowledgements**

Authors are grateful to the staff of the Department of Pharmacognosy and Natural Medicine, Faculty of Pharmacy, University of Uyo. Mr. N. Malachy, of the Animal House, Dept. of Pharmacology and Toxicology, University of Uyo, Nigeria, is also appreciated for his technical assistance.

**Author’s contributions**

UP designed the study, interpreted the results, and wrote the manuscript. EE did statistical analysis of the results and reviewed manuscript. UE did the experiments. IE and RS assisted in the writing of the manuscript. All read and confirmed the final edition for publication.

**Conflict of interests**

Authors declare that no competing interest exists.

**Ethical Considerations**

All experiments involving the use of these mice were approved by the Animal Ethics Committee of the Faculty of Pharmacy, University of Uyo, Nigeria (UUP 17).

**Funding/Support**

Education Trust Fund (ETF) of the University of Uyo supported the study (UU030).

**References**

1. Soko W, Chimbari MJ, Mukaratirwa S. Insecticide resistance in malaria-transmitting mosquitoes in Zimbabwe: a review. Infect Dis Poverty. 2015;4:46. doi: 10.1186/s40249-015-0076-7.

2. Singh S. Current scenario of control of malaria. Trop Parasitol. 2011;11(2):52-3. doi: 10.4103/2229-5070.86922.

3. World Health Organization (WHO). Guidelines for the treatment of malaria. 3rd ed. Geneva, Switzerland: WHO Press; 2015:45-7.

4. World Health Organization (WHO). WHO Global Work on Malaria. World Malaria Report, 2015. https://www.who.int/malaria/publications/world-malaria-report-2015/report/en/. Accessed January 5, 2018.

5. Ariey F, Witkowski B, Amarurutanga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant *Plasmodium falciparum* malaria. Nature. 2014;505(7481):50-5. doi: 10.1038/nature12876.

6. World Health Organization (WHO). WHO Malaria Vaccine Development. Immunization, Vaccines and Biologicals. https://www.who.int/immunization/research/development/malaria/en/.

7. Okokon JE, Ubolum PM, Udokoh AE. Antiplasmodial activity of *Setaria megaphylla*. Phytother Res. 2007;21(4):366-8. doi: 10.1002/ptr.2059.

8. Adugna M, Feyera T, Taddese W, Admasu P. In vivo antimalarial activity of crude extract of aerial part of *artemisia abyssinica* against *Plasmodium berghei* in mice. Global J Pharmacol. 2014;8(3):460-8. doi: 10.5829/idosi.gjp.2014.8.3.822.

9. Ettebong EO, Ubolum P, Ekpenyong C, Ekong SU, Akpan EO, Tambari DV. In vivo antimalarial activities of *Nauclea latifolia*. Asian J Med Sci. 2015;6(3):6-11. doi: 10.3126/ajms.v6i3.11361.

10. Bankole AE, Adekunle AA, Sowemimo AA, Umehese CE, Abiodun O, Gbotosho GO. Phytochemical screening and in vivo antimalarial activity of extracts from three medicinal plants used in malaria treatment in Nigeria. Parasitol Res. 2016;115(1):299-305. doi: 10.1007/s00436-015-4747-x.

11. Ubolum P, Alozie Mfon F, Umoinyang A. Evaluation of in vivo antimalarial efficacy of ethanolic leaf and root extracts of *Alchornea cordifolia*. World J Pharm Res. 2018;7(3):1296-305. doi: 10.20959/wjpr20183-10033.

12. Junior EMda, Fernandes IMds, Santos CS, Mesquita Lxd, Pereira RA, Maracaja PB, et al. Toxicity of castor bean (*Ricinus communis*) pollen to honeybees. Agric Ecosyst Environ. 2011;141(1-2):221-3. doi: 10.1016/j.agee.2011.02.010.

13. Ezenobi UV, Amaku FJ, Agbien C. Ricinus Communs seeds (ogiri-okpei) and its phytochemical composition. Global J Engr Sci Res. 2016;3(7):6-13.

14. Lorke D. A new approach to practical acute toxicity testing. Arch Toxicol. 1983;54(4):275-87.

15. Muthaura CN, Rukungwa GM, Chhabra SC, Omar SA, Guantai AN, Gathirwa JW, et al. Antimalarial activity of some plants traditionally used in Meru district of Kenya. Phytother Res. 2007;21(9):860-7. doi: 10.1002/ptr.2170.

16. Ettebong EO, Etuk EU, Ubolum P, Ekpenyong C, Okokon JE, Udobi CE, et al. Antiplasmodial and antidiarrhoeal activities of *Dicliptera verticillata* leaf extract. J Phytopharmacol. 2015;4(2):73-9.

17. World Health Organization (WHO). International Pharmacopoeia. 3rd ed. Quality Specifications for Pharmaceutical Substances. Geneva: WHO; 2009. p. 228.

18. Okokon JE, Ettebong EO, Udobang JA, Obot J.
Antiplasmodial and antiulcer activities of *Melanthera scadens*. Asian Pac J Trop Biomed. 2012;2(1):16-20. doi: 10.1016/s2221-1691(11)60182-2.

19. Deressa T, Meckonnen Y, Animut A. In Vivo anti-malarial activities of *Clerodendrum myricoides*, *Dodonea angustifolia* and *Aloe debrana* against *Plasmodium berghei*. Ethiop J Health Dev. 2010;24(1):25-9. doi: 10.4314/ejhd.v24i1.62941.

20. Unekwuojo EG, James O, Olubunmi AR. Suppressive, curative and prophylactic potentials of *Morinda lucida* (Benth) against, erythrocytic stage of mice infected with Chloroquine sensitive Plasmodium berghei. Br J Appl Sci Technol. 2011;1(3):131-40. doi: 10.9734/BJAST/2011/273. 21. Loomis TA, Hayes AW. Loomis Essentials of Toxicology. 4th ed. California: Academic Press; 1996:23-59.

22. Celikel N, Kavas G. Antimicrobial properties of some essential oils against some pathogenic microorganisms. Czech J Food Sci. 2015;26(3):174-81.

23. Bero J, Frederick M, Quetin-Leclercq J. Antimalarial compounds isolated from plants used in traditional medicine. J Pharm Pharmacol. 2009;61(11):1401-33. doi: 10.1211/jpp/61.11.0001.

24. Dawodu AO, Moses UD, Apena A, Adetoro A, Dairo JO. The proximate evaluation and phytochemistry of *Enantia chlorantha* stem bark in aqueous and ethanolic extract Middle-East Journal of Scientific Research. 2014;21(11):2145-8. doi: 10.5829/idosi.mejsr.2014.21.11.21842.

25. Ihoekereme CP, Agbata CA, Chukwueze KO, Agu SC. In vivo evaluation of antimalplasmodial activity of hydroethanolic stem extract of *Baphia pubescens* in *Plasmodium berghei* infected albino mice. J HerbMed Pharmacol. 2016;5(4):149-152.

26. Azebaze AG, Meyer M, Valentin A, Nguemfo EL, Fomum ZT, Nkengfack AE. Prenylated xanthone derivatives with antimalplasmodial activity from *Allanblackia monticola* STANER L.C. Chem Pharm Bull (Tokyo). 2006;54(1):111-3. doi: 10.1248/cpb.54.111.

27. Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas N, Mshvildadze V, et al. Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. Planta Med. 2000;66(4):343-7. doi: 10.1055/s-2000-8541.

28. Liu KC, Yang SL, Roberts MF, Elford BC, Phillipson JD. Antimalarial activity of *Artemisia annua* flavonoids from whole plants and cell cultures. Plant Cell Rep. 1992;11(12):637-40. doi: 10.1007/bf00236389.

29. Ngemenya M, Titanji V, Akam T, Yong J, Tane PF, Berzinsk S. Antiplasmodial activity and toxicity of extracts and products from selected medicinal plants used in Cameroon. Acta Trop. 2015;96(1):50-6.

30. Krettli AU, Adebayo JO, Krettli LG. Testing of natural products and synthetic molecules aiming at new antimalarials. Curr Drug Targets. 2009;10(3):261-70.